WASHINGTON -- An investigational non-surgical treatment led to a "robust" complete response rate in patients with recurrent, low-grade non-muscle-invasive bladder cancer, the phase III ENVISION study ...
The current standard of care for high-risk superficial bladder cancer is intravesical bacillus Calmette–Guérin (BCG). Electromotive mitomycin has also shown efficacy against high-risk superficial ...
INTRAVESICAL INSTILLATION of cytotoxic chemotherapy or immunotherapy is used to treat existing tumors, reduce or postpone tumor recurrence, and delay or prevent tumor progression and subsequent ...
Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy. Background: Combination chemotherapy is the standard of care for neoadjuvant, adjuvant, and metastatic bladder ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Intravesical therapy is widely used in practice as an adjuvant treatment for early-stage bladder cancer following surgical transurethral resection. This is because it is a localized treatment that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results